Iron metabolism is a balancing act, and biological systems have evolved exquisite
regulatory mechanisms to maintain iron homeostasis. Iron metabolism disorders are …

Heart failure (HF) is highlighted by its burdening symptom-limited exercise capacity and
recurrent hospitalizations. Despite substantial advances regarding disease-modifying drugs …

Non-anaemic iron deficiency (NAID) is a strategic target in cardiovascular medicine because
of its association with a range of adverse effects in various conditions. Endeavours to tackle …

Aims How often a medical article is cited is important for many people because it is used to
calculate different variables such as the h‐index and the journal impact factor. The aim of …

Intravenous ferric carboxymaltose (Ferinject®; Injectafer®) is a colloidal solution of
nanoparticles which consist of a polynuclear iron (III)-(oxyhydr) oxide core stabilized by …

Aims Iron deficiency (ID) is comorbid in up to 50% patients with heart failure (HF) and
exacerbates disease burden. Ferric carboxymaltose (FCM) reduced HF hospitalizations and …

In an aging population, the number of patients affected by heart failure and cancer is
constantly increasing and together these two conditions account for more than 50% of all …

Aims Intravenous ferric carboxymaltose (FCM) has been shown to improve functional
capacity and quality of life in iron deficient heart failure patients. However, FCM's effect on …

Aims This analysis aims to evaluate the budget impact of intravenous iron therapy with ferric
carboxymaltose for patients with systolic chronic heart failure and iron deficiency, from the …

Aim: To evaluate the cost–effectiveness of intravenous ferric carboxymaltose (FCM) versus
placebo for the management of iron deficiency in patients with chronic heart failure in the …